Multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphism: from discovery to clinical application by Yin, Jiye & Zhang, Jianting
Multidrug resistance-associated protein 1 (MRP1/ABCC1) 
polymorphism: from discovery to clinical application
YIN Jiye1,2 and ZHANG Jianting1,2
1
 Department of Pharmacology/Toxicology, Indiana University School of Medicine, Indianapolis 
Indiana 46202, USA
2
 IU Simon Cancer Center, Indiana University School of Medicine, Indianapolis Indiana 46202, 
USA
Abstract
Multidrug resistance-associated protein 1 (MRP1/ABCC1) is the first identified member of ABCC 
subfamily which belongs to ATP-binding cassette (ABC) transporter superfamily. It is 
ubiquitously expressed in almost all human tissues and transports a wide spectrum of substrates 
including drugs, heavy metal anions, toxicants, and conjugates of glutathione, glucuronide and 
sulfate. With the advance of sequence technology, many MRP1/ABCC1 polymorphisms have been 
identified. Accumulating evidences show that some polymorphisms are significantly associated 
with drug resistance and disease susceptibility. In vitro reconstitution studies have also unveiled 
the mechanism for some polymorphisms. In this review, we present recent advances in 
understanding the role and mechanism of MRP1/ABCC1 polymorphisms in drug resistance, 
toxicity, disease susceptibility and severity, prognosis prediction, and methods to select and 
predict functional polymorphisms.
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Multidrug resistance-associated protein 1 (MRP1/ABCC1) is a member of the ATP-binding 
cassette (ABC) transporter superfamily which contains 49 members in human that are 
divided into 7 subfamilies, named from ABCA to ABCG (http://nutrigene.4t.com/
humanabc.htm)[1-2]. MRP1/ABCC1 is the first identified gene in the ABCC subfamily and 
was cloned from a multidrug resistant small cell lung cancer cell line H69AR[3]. Subsequent 
studies revealed the important role of MRP1/ABCC1 as an exporter of drugs and 
metabolites in many physiological, pathological and pharmacological processes. Thus, 
polymorphism is likely an important feature of MRP1/ABCC1 in disease susceptibility, drug 
response, and treatment outcomes[4]. In this review, we will evaluate recent advances in 
discovery of MRP1/ABCC1 polymorphisms and understanding their potential clinical 
applications.
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1 STRUCTURE AND TISSUE DISTRIBUTION
The MRP1/ABCC1 gene is located in chromosome 16p13. 1 and spans approximately 200 
kb. It contains 31 exons and encodes a protein of 1 531 amino acid residues with an apparent 
molecular weight of 180-190 kD[3-5]. MRP1/ABCC1 is an atypical ABC transporter with 
three membrane-spanning domains (MSD) and two cytosolic nucleotide binding domains 
(NBD) [6]. While MSD1 and MSD2 each consists of 6 transmembrane ( TM) segments, 
MSD0 has 5 TM segments with a predicted extracellular amino terminus (Fig. 1A). 
However, recent studies showed that the amino terminus of human MRP1/ABCC1 may have 
an unusual U-shaped structure which possibly serves as a gate for MRP1/ABCC1 
function[7-9].
The sequence of MSD is highly divergent among different members of ABC transporter 
family, consistent with MSD’s possible function in determining substrate specificity[10]. 
Thus, polymorphisms in this domain may affect the substrate spectrum of MRP1/ABCC1. 
While a typical ABC transporter has two MSDs, the additional MSD0 of human MRP1/
ABCC1 is peculiar and its function is not yet fully elucidated. However, our recent studies 
showed that MSD0 contributes to MRP1/ABCC1 homo-dimerization[11-12].
In contrast to MSD, NBD is highly conserved among different ABC transporters. It is 
responsible for binding and hydrolysis of ATP to provide energy for substrate transport[10]. 
Similar to other ABC transporters, the NBD of MRP1/ABCC1 has two consensus motifs 
designated as “Walker A” and “Walker B”[13] and a third consensus motif designated as 
ABC-signature motif of approximate 13 amino acids between Walker A and Walker B[10]. 
These highly conserved motifs are critical for MRP1/ABCC1 function and a single mutation 
may abolish the activity of the whole protein[14-15]. Thus, polymorphisms in NBD may 
produce inactive MRP1/ABCC1.
MRP1/ABCC1 appears to be ubiquitously expressed in almost all human tissues[16-18]. Its 
expression level is high in lung, spleen, testis, kidney, placenta, thyroid, bladder and adrenal 
gland, but low or no expression in some cells of circulatory system, such as eosinophils, 
helper T-cells and erythrocytes[19]. MRP1/ABCC1 is also expressed in blood-brain, blood-
testis and blood-cerebrospinal fluid (CSF) barriers, which was thought to contribute to 
protection of these organs by keeping out toxic substances[20-21]. Indeed, it has been shown 
that accumulation of etoposide in CSF increased 10-fold in MRP1/ABCC1 knockout 
mice[20]. At the cellular level, in contrast to the apical membrane location of other ABC 
transporters, MRP1/ABCC1 is predominantly located in the basolateral membrane of 
polarized cells[22-23]. Thus, MRP1/ABCC1 likely pumps its substrate into the interstitial 
space of body, rather than excreting them into bile, urine or gut.
2 SUBSTRATES
MRP1/ABCC1 can transport a wide spectrum of substrates ranging from anticancer drugs to 
fluorescent dye (Tab. 1). A wide variety of anticancer drugs including anthracyclines, 
epipodophyllotoxins, vinca alkaloids, camptothecins, methotrexate and mitoxantrone are 
known substrates of MRP1/ABCC1 and, thus, MRP1/ABCC1 over-expression leads to 
multidrug resistance in cancer chemotherapy. In addition to anticancer drugs, MRP1/
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ABCC1 also transports many other types of drugs, such as anti-HIV drugs. Therefore, 
MRP1/ABCC1 gene polymorphisms may affect patient response to chemotherapy of these 
diseases. Previously, we have shown that G2168A polymorphism significantly reduced 
MRP1/ABCC1 activity in resistance to anthracyclines, vinca alkaloids and etoposide[24].
Another important group of substrates of MRP1/ABCC1 is organic anion conjugates 
including glutathione, glucuronides and sulfate conjugates. Transporting these conjugates 
helps cells to remove toxins and protect tissues from damage[25-26]. LTC4, a very 
important mediator of inflammatory response which controls vascular permeability and 
smooth muscle contraction, is another high affinity substrate of MRP1/ABCC1[19,27]. Thus, 
MRP1/ABCC1 polymorphisms may affect therapeutic efficiency of some LTC4 targeting 
drugs, such as montelukast and zileuton [28-29].
3 POLYMORPHISMS
A large number of naturally occurrmg MRP1/ABCC1 polymorphisms have been identified 
with most studies in Asian and Caucasian populations[30-37]. A comprehensive list of 
naturally occurring MRP1/ABCC1 polymorphisms in different populations can be found in 
several publicly accessible databases [Pharmacogenetics Research Network: http://
www.pharmgkb.org; National Central for Biotechnology Information (NCBI): http://
www.ncbi.nlm.nih.gov/snp; Japanese Single Nucleotide Polymorphisms (JSNP) database: 
http://snp.ims.u-tokyo.ac.jp/; International HapMap Project: www.hapmap.org/].
Most identified MRP1/ABCC1 polymorphisms are single nucleotide polymorphisms (SNPs), 
although repeats, insertions and deletions are also found. There are vast ethnical differences 
in MRP1/ABCC1 polymorphism distribution and frequency, especially between Asian and 
Caucasian. For example, G2168A is a common SNP in the Asian population, but it has not 
been found in Caucasian[24]. On the contrary, G2012T polymorphism is common in 
Caucasian, but not found in Asian populations [31]. Most MRP1/ABCC1 polymorphisms 
have a very low frequency (< 5%), which indicating that MRP1/ABCC1 is a highly 
conserved gene. The majority of identified polymorphisms are located in the untranslational 
region (UTR) and introns and few polymorphisms are located in the coding region. 
Polymorphisms in the coding region are more likely to be functional and can be divided into 
three types: synonymous (no change in amino acid sequence resulting in a wild-type 
protein), non-synonymous (change in amino acid sequence resulting in a mutant protein), 
and nonsense (change to a stop codon resulting in a truncated protein). Up to date, only 14 
non-synonymous polymorphisms have been identified with very low frequencies and no 
nonsense polymorphism has been found (Fig. 1). These non-synonymous polymorphisms 
were intensively studied both in vitro and in vivo since they could be easily recreated using 
site-directed mutagenesis and they might affect the expression and function of MRP1/
ABCC1[24-39]. Although the polymorphisms in the non-coding region do not affect the 
sequence of the protein, they are also important and can be used as genetic markers[40-41].
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4 ASSOCIATION OF MRP1/ABCC1 POLYMORPHISMS WITH THERAPEUTIC 
RESPONSE
As discussed above, many therapeutic drugs are substrates of MRP1/ABCC1. Thus, it is 
conceivable that some MRP1/ABCC1 polymorphisms may affect treatment responses and 
toxicities. Tab. 2 lists MRP1/ABCC1 polymorphisms that have been studied for their 
association with therapeutic responses. One of these polymorphisms, G2012T which was 
first identified by Conrad et al.[34] in Caucasian population, has been extensively studied. It 
causes mutation of a highly conserved Gly671 to Val. Investigation of its potential 
relationship with response to atorvastatin in treatment of hypercholesterolemia, telatinib in 
treatment of solid tumors, and induction therapy of leukemia, however, showed no 
significant correlattion with treatment responses[42-44]. Consistent with these clinical 
observations, in vitro studies also showed that the mutant MRP1/ABCC1 carrying this 
mutation had no detectable difference in drug transport activity from the wild type MRP1/
ABCC1 [34], Thus, the G2012T polymorphism may not have functional impact on 
chemotherapy.
Another extensively studied polymorphism is G4002A, a synonymous SNP located in exon 
28. Several studies exploring the correlation of G4002A polymorphism and responses to 
anticancer drugs gemcitabine, cisplatin, taxanes and methotrexate showed no significant 
association in pancreatic cancer patients [45-47]. However, Lee et al. [48] found that this 
polymorphism was strongly associated with the response of patients with major depressive 
disorder to antidepressant citalopram. Although patients with the G4002A polymorphism 
had a 4. 7-fold increase in citalopram response, there is no evidence that G4002A 
polymorphism of MRP1/ABCC1 in the blood-brain barrier affects citalopram uptake and if 
citalopram is a substrate of MRP1/ABCC1. Another non-synonymous polymorphism 
located in exon 28, A4009G, was found to correlate with methotrexate therapeutic efficacy 
in a study of 374 chronic plaque psoriasis patients who received methotrexate 
monotherapy[49]. It was found that the heterozygous A4009G in the responders is 
significantly higher than that in non-responders, suggesting that the A4009G polymorphism 
may increase methotrexate responses. However, it has not yet been determined if the 
A4009G polymorphism affects MRP1/ABCC1 expression, trafficking, or function. Future 
studies on the possible effects of the A4009G polymorphism on these aspects of MRP1/
ABCC1 are needed.
A well studied polymorphism that has been shown to significantly reduce drug transport 
activity of MRP1/ABCC1 is G2168A[24]. It has also been shown to increase chemotherapy 
response in advanced ovarian cancer patients[50]. In the study of advanced ovarian cancer 
patients, several other polymorphisms of MRP1/ABCC1 (T825C, T1062C, T1684C, C2007T 
and G4002A) were also investigated. However, none of these polymorphisms were found to 
significantly associate with chemotherapy responses. Thus, the G2168A polymorphism may 
be an indicator of chemotherapy response of advanced ovarian cancers. However, whether 
this polymorphism also affects chemotherapy responses of other human cancers need to be 
investigated.
Jiye and Jianting Page 4
Zhong Nan Da Xue Xue Bao Yi Xue Ban. Author manuscript; available in PMC 2015 January 17.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
In addition to the polymorphisms in the coding region, some polymorphisms in the non-
coding region of MRP1/ABCC1 are also found to associate with drug responses. Two such 
polymorphisms in the non-coding region are IVS23 G-1960A and IVS9 T-176C located in 
intron 23 and 9, respectively. They both have been shown to significantly associate with 
methotrexate response in psoriasis patients and patients carrying these polymorphisms 
appear to have worse response to methotrexate treatment[49]. Another example of 
polymorphisms in the non-coding region is IVSI C-14840T which is located in intron 1 and 
has been found to correlate with significantly higher response to both montelukast and 
zileuton in asthma patients than wild-type homozygotes [28-29]. Thus, polymorphisms in 
MRP1/ABCC1 may affect montelukast and zileuton response and lung function. 
Interestingly, in another study of two independent cohorts, polymorphisms of MRP1/ABCC1 
in the 3'-UTR (G3361A and A2615G) and IVS14 C-1575T also significantly correlate with 
lung function[51]. While 3'-UTR G3361A correlates with higher forced expiratory volume at 
one second (FEV1), 3'-UTR A2615G correlates with lower FEVI. Another polymorphism, 
IVS14 C-1575T in the intron 14 of MRP1/ABCC1, correlates with highly excessive FEVI 
decline. However, how these polymorphisms in the non-coding region possibly affect 
MRP1/ABCC1 is not yet known. It is also unknown if MRP1/ABCC1 plays any role in lung 
function. While the polymorphisms in the UTR may affect the translation and expression of 
MRP1/ABCC1, the polymorphisms in the intron may affect RNA processing. Clearly, these 
hypothetical mechanisms of action and the role of MRP1/ABCC1 in lung function needs to 
be investigated in the near future.
5 ASSOCIATION OF MRP1/ABCC1 POLYMORPHISMS WITH PROGNOSIS 
PREDICTION
Based on the above discussion of association of MRP1/ABCC1 polymorphisms with 
therapeutic response, it is tempting to speculate that polymorphisms of MRP1/ABCC1 may 
be used as markers to predict prognosis. Indeed, two polymorphisms have been shown to 
associate with prognosis (Tab. 3). In a study of possible contribution of four non-
synonymous polymorphisms of MRP1/ABCC1 to neuroblastoma outcome in a cohort of 195 
Caucasian patients, it was found that the presence of the G2010T polymorphism has 
significant improvement in outcome[52]. It was also found that the G2010T polymorphism 
reduces the stability and expression level of MRP1/ABCC1 mRNA. Hence, it is possible that 
patients with the G2010T polymorphism may have reduced level of MRP1/ABCC1, which 
would enhance drug response and increase chemotherapy efficacy. In another study of 
correlating 5'-UTR G-1666A polymorphism with hepatocellular carcinoma (HCC) outcome 
in 162 Chinese patients, it was found that the mutant genotype carriers had better prognosis 
with increased 4-year disease free survival[53]. Using in vitro electrophoretic mobility shift 
assay (EMSA), these authors also found that the mutant allele had much less binding affinity 
to nuclear proteins, suggesting that this promoter polymorphism may cause decreased 
transcription of MRP1/ABCC1. However, whether this promoter polymorphism inhibits 
MRP1/ABCC1 transcription has not yet been demonstrated. It is also unknown if the nuclear 
proteins that bind to this region are involved in the transcription of MRP1/ABCC1. Never-
theless, these polymorphisms may be used as makers predicting prognosis and survival in 
neuroblastoma and HCC.
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6 ASSOCIATION OF MRP1/ABCC1 POLYMORPHISMS WITH DRUG 
TOXICITY
Since some toxicants and drug metabolites are also substrates of MRP1/ABCC1, possible 
association of MRP1/ABCC1 polymorphisms and drug toxicity is also of importance and 
interest to investigate. In this regard, correlation of MRP1/ABCC1 polymorphisms and drug-
induced neuropathy is mostly studied (Tab. 4). In a recent study correlating polymorphisms 
of MRP1/ABCC1 (IVS9A8G, IVS11C-48T, T1684C, IVS18C-30G, G4002A and 
IVS30A18G) with irinotecan-induced neutropenia in cancer patients, it was found that the 
TT genotype carriers of IVSI1 C-48T had significant lower neutrophil count (ANC) in 
patients receiving irinotecan monotherapy[54]. Irinotecan-induced neutropenia is thought to 
be due to production of the cytotoxic irinotecan metabolite, SN-38, which is a substrate of 
MRP1/ABCC1. Consistent with this study, MRP1/ABCC1 polymorphism has also been 
found to correlate with peripheral neuropathy induced by vincristine[55]. In this study of 833 
myeloma patients, it was found that the carriers of MRP1/ABCC1 polymorphism IVS16 
A1695T were more likely to develop vincristine-induced peripheral neuropathy than the 
wild type carriers. Similar to SN-38, it is also speculated that this polymorphism may 
decrease MRP1/ABCC1-mediated transport of vincristine and, thus, increases vincrinstine-
induced peripheral neuropathy. However, the molecular mechanisms need further 
investigation.
One interesting polymorphism is G2012T, which shows correlation with doxorubicin 
toxicity in non-Hodgkin lymphoma patients[56]. The patients with this polymorphism have 
more anthracycline-induced cardiotoxicity than the wild-type patients. It was thought that 
the special subcellular localization of MRP1/ABCC1 in cardiomyocytes, in both plasma and 
lysosome membranes, permits sequestration of doxorubicin in lysosomes and prevent 
doxorubicin cardiotoxicity[17-57]. However, it has been demonstrated previously that the 
G2012T polymorphism of MRP1/ABCC1 has no effect on its function and substrate 
transport activity[34]. Thus, it is not clear how this polymorphism affects anthrocycline-
induced cardiotoxicity. Furthermore, since multidrug chemotherapy was used for these 
cohorts of patients, interpretation of these observations should be cautious. Doxorubicin 
mono-therapy and further investigation of G2012T mutation on MRP1/ABCC1 activity in 
transporting doxorubicin would help clarify this issue.
Several other polymorphisms of MRP1/ABCC1 (IVS3 G-3198A, IVS4 G409A, 
IVS5G413A, IVS5 A-7942G, IVS5G-1641A and IVS23 G-1960A) have been found to 
significantly correlate with methotrexate toxicity in liver and GI tract of psoriasis 
patients[49]. All these polymorphisms are located in introns and form a haplotype although it 
is not yet known if they affect the expression of MRP1/ABCC1 individually or as a 
haplotype. Based on the above discussion, MRP1/ABCC1 polymorphisms are likely 
important genetic indicators in drug toxicity during chemotherapy.
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7 ASSOCIATION OF MRP1/ABCC1 POLYMORPHISMS WITH DISEASE 
SUSCEPTIBILITY AND SEVERITY
Association of MRP1/ABCC1 with disease susceptibility has also been identified (Tab. 5). 
In a case control study of 500 lung cancer patients and 517 cancer free control subjects in 
Chinese population, Wang et al. [58] detected the association of three polymorphisms in the 
3'-UTR of MRP1/ABCC1 (C543T, T866A and T1512C) with lung cancer susceptibility. 
They found that subjects carrying mutant allele of 3'-UTR T866A had an increased risk of 
lung cancer. However, the other two polymorphisms had no significant correlation with lung 
cancer susceptibility. Further investigation showed that these three polymorphisms form a 
haplotype and the GTA haplotype was associated with increased risk of lung cancer 
compared with the most prevailing AAA haplotype. Therefore, this polymorphism 
haplotype may increase lung cancer predisposition in Chinese population. We recently 
identified association of another non-synonymous polymorphism G2168A with lung cancer 
susceptibility[59]. In our study of 77 lung cancer patients and 71 control individuals in 
Chinese population, we showed that the subjects carrying the G2168A allele had 3. 5 fold 
increased risk (adjusted OR = 3. 42; 95% CI, 1. 29 - 9. 06; P =0. 013) of lung cancer 
compared with wild-type carriers. Further stratified analysis showed that the elderly people 
(> 50 years) carrying mutant allele of this polymorphisms were more likely to develop lung 
cancer (adjusted OR, 4. 10; 95% CI, 1. 25-13. 48; P =0. 020) than younger ones. Taken 
together, it is possible that MRP1/ABCC1 polymorphisms may play important roles in lung 
cancer susceptibility. Although the mechanism of MRP1/ABCC1 action in lung cancer 
susceptibility is unknown, it is tempting to speculate that MRP1/ABCC1 may protect lung 
tissues against carcinogens by preventing them from entering bronchial epithelial cells. 
Carriers of these MRP1/ABCC1 polymorphisms are likely more susceptible to 
carcinogenesis due to reduced protection by MRP1/ABCC1. This possibility is consistent 
with our observation that the G2168A polymorphism decreases MRP1/ABCC1 function in 
drug transport activity (unpublished observations). However, further clinical studies are 
needed to test this possibility.
Possible impact of MRP1/ABCC1 polymorphisms on disease severity has also been reported 
in other studies (Tab. 5). In a study of 203 cystic fibrosis (CF) patients, it was found that the 
G-260C polymorphism in the 5'-UTR of MRP1/ABCC1 significantly increased CF 
severity[60]. Patients with CC genotype had earlier onset of chronic colonization by 
Pseudomonas aeruginosa (PA). Although in vitro study showed no impact of this 
polymorphism on promoter transcriptional activity, mRNA levels, basal and cAMP-induced 
anion transport, the possibility that this polymorphism affects translation/synthesis of 
MRP1/ABCC1 and, thus, its expression level cannot be ruled out.
In another study of five MRP1/ABCC1 polymorphisms (3'-UTR T866A, 3'-UTR G3361A, 
5'-UTR C-435G, IVSl T5977G and IVS14 C-1575T) and their possible effect on chronic 
obstructive pulmonary disease (COPD) severity, it was found that the 3'-UTR T866A was 
associated with higher FEV1 level and less airway wall inflammation while the 3'-UTR 
G3361A was associated with lower FEV1 level and higher inflammation. However, the 
other three polymorphisms have no significant association with COPD severity[61]. The 
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mechanism of the 3'-UTR T866A in affecting COPD severity remains unknown. However, 
it is speculated that 3'-UTR T866A may affect MRP1/ABCC1 mRNA stability together with 
another 3'-UTR polymorphism 801 C > GR[51-61] They were found to be in complete 
linkage disequilibrium[40]. Clearly, MRP1/ABCC1 polymorphisms are likely associated with 
lung cancer susceptibility and with COPD and CF disease severity. However, whether and 
how each polymorphism possibly affects disease susceptibility and severity need to be 
investigated in the future.
8 CONCLUSIONS SPECTIVES
Since the discovery of MRP1/ABCC1 in 1992, many MRP1/ABCC1 polymorphisms have 
been identified. Most of the identified polymorphisms are synonymous and have low 
frequency, indicating that MRP1/ABCC1 is a highly conserved gene. Some of the MRP1/
ABCC1 polymorphisms have been found to associate with drug response, prognosis, 
toxicity, disease susceptibility and severity. Some of these polymorphisms have also been 
shown to affect MRP1/ABCC1 expression or function which may indicate the underling 
mechanism of association with the observed phenotype. With the advances of next 
generation sequencing, International HapMap Project and 1 000 Genomes Project[62-63], 
more MRP1/ABCC1 polymorphisms are likely to be identified. However, identifying 
functional MRP1/ABCC1 polymorphisms and their mechanisms of action will not be easy. 
Thus, both opportunities and challenges exist.
Because not every polymorphism is functional, selecting potentially functional 
polymorphisms for further clinical relevance study is important considering the large 
number of polymorphisms is to be identified. Use of in silico and bioinformatics tools such 
as SIFT, PANTHER and Polyphen algorithms to detect sequence conservation can help 
identify the likely functional polymorphism since sequences that are highly conserved across 
different species tend to be functionally important[64-66]. However, this strategy should be 
used with caution due to both false positive and negative predictions. For example, G689A, 
G1057A and G3173A polymorphisms of MRP1/ABCC1 are predicted as deleterious 
polymorphisms using SIFT. However, none of these polymorphisms adversely affects 
MRP1/ABCC1 function[24-39].
Examination of polymorphism databases shows that most polymorphisms are located in 
introns and UTRs. In addition, some polymorphisms located in the exons are synonymous 
polymorphisms. Thus, study of sequence conservation will unlikely be able to predict if 
these polymorphisms are functional. For these polymorphisms, a genome-wide approach to 
identify polymorphisms of positive and negative selection is helpful[41-67]. Positive selection 
is an evolutionary process and the positively selected polymorphisms contribute to the 
favorable phenotype of species and, thus, these polymorphisms may be of higher frequency 
in the population and important for the gene function[66-68]. Opposite to positive selection, 
negative selection is the decline of disadvantage phenotype and harmful and, thus, the 
negatively selected polymorphisms usually have very low frequency (minor allele frequency 
< 0. 05) in the population although they may be important for the function and rare drug 
adverse effects[66]. Both strategies have been used to identify functional MRP1/ABCC1 
polymorphisms[38,41,56,67]. However, it is noteworthy that combination of sequence 
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conservation and evolutionary features may be more powerful than any approach alone to 
predict and identify functional polymorphisms.
Another challenge is to understand how each polymorphism affects gene function. While it 
is easy to study the effect of the non-synonymous polymorphisms on the structure and 
function of MRP1/ABCC1 by re-creating the mutant protein and analyzing the protein in 
cell lines[24-39], it is challenging to investigate the synonymous or non-coding region 
polymorphisms due to complexity of their functional gene effect by different mechanisms 
such as transcription, splicing, RNA stability, and combined haplotype [40, 49, 53, 69-70].
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Fig. 1. 
A:Schematic representation of the topological structure of MRP1/ABCC1 protein predicted 
using TOPO2 program with modification (http://www.sacs.ucsf.edu/TOPO-run/wtopo.pl). 
The consensus sequences of Walker A and B are highlighted in orange and green, 
respectively. The ABC-signature motif is highlighted in red. TM, transmembrane; MSD, 
membrane spanning domain; NBD, nucleotide-binding domain. B: Distribution of clinically 
relevant MRP1/ABCC1 exon polymorphisms.
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Tab. 1
Clinically relevant substrates of MRP1/ABCC1 *
Type of substrates Examples
Drugs Anticancer drugs
 Vinca alkaloids: vinblastine and vincristine
 Epipodophyllotoxins: etoposide (VP-16) and teniposide
 Camptothecins: topotecan, irinotecan and SN-38
 Methotrexate and mitoxantrone
Other drugs
 Anti HIV drugs; ritonavir and saquinavir
 Antibiotics: difloxacin and grepafloxicin
 Tyrosine kinase inhibitors: imatinib mesylate and gefitinib
Heavy metal anions Arsenite
Arsenate
Trivalent and pentavalent antimonials
Glutathione conjugates(-GS) Dinitrophenyl-GS
Etacrynic acid-GS
Doxorubicin-GS
Cyclophosphamide-GS
Melphalan-GS
Aflatoxin B1-epoxide-GS
Hydroxynonenal-GS
Prostaglandin A2-GS
Glutathione (GSH, GSSG)
Glucuronide conjugates (-G) Bilirubin-G
Estradiol 17βD-G
Hyodeoxycholate-G
Etoposide (VP-16)-G
NS-38-G
Sulfate conjugates (-S) Estrone-3-S
Taurocholate-3-S
Dehydroepiandrosterone-3-S
Sulfatolithocholyl taurine
Folates Folic acid
L-leucovorin
Toxicants Aflatoxin B1
Methoxychlor
Fenitrothion
Others Leukotrienes C4, D4 and E4
Curcuminoids
Calcein
*
The primary references are available from the following reviews. [1, 10, 19, 71]
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Tab. 2
Association of MRP1/ABCC1 polymorphisms with therapeutic response
Polymorphisms rs number Amino acid exchange Location Drugs Disease/Observation References
G2012T rs45511401 Gly671Val Exon 16 Atorvastatin Hypercholesterolemia/No correlation [42]
Telatinib Solid tumor/No correlation [44]
Induction Therapy Leukemia/No correlation [43]
G4002A rs2239330 No change Exon 28 Gemcitabine, 
cisplatin, taxane, 
methotrexate
Pancreatic cancer/No correlation [45-47]
Citalopram Major depressive disorder/Strong 
correlation
[48]
G2168A rs4148356 Arg723Gln Exon 17 Platinum Ovarian cancer/Correlation [50]
Taxane Ovarian cancer/Correlation [50]
A4009G rs28364006 Alal337Thr Exon 28 Methotrexate Psoriasis/Correlation [49]
IVS23 G-1960A rs2238476 No change Intron 23 Methotrexate Psoriasis/Correlation [49]
IVS9 T-176C rs35592 No change Intron 9 Methotrexate Psoriasis/Correlation [49]
T2684C No change Exon 21 Leukemic/No correlation [43]
C2007T rs2301666 No change Exon 16 Leukemic/No correlation [43]
G2012T rs45511401 Gly671Val Exon 16 Leukemic/No correlation [43]
C2665T No change Exon 21 Leukemic/No correlation [43]
IVS1 C-14840T rsll9774 No change Intron 1 Montelukast Asthma/Correlation [28]
Zileuton Asthma/Correlation [29]
GCC repeat No change 5′UTR Azithromycin Cystic fibrosis/No correlation [72]
IVS18 C -30G rs2074087 No change Intron 18 Taxanes Ovarian cancer/No correlation [47]
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Tab. 3
Association of MRP1/ABCC1 polymorphisms with prognosis prediction
Polymorphisms rs number Amino acid exchange Location Disease/Observation References
G2012T rs45511401 Gly671Val Exon 16 Neuroblastoma/Correlation [52]
5′-UTR G-1666A rs4148330 No change 5′UTR Hepatocellular carcinoma/Correlation [53]
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Tab. 4
Association of MRP1/ABCCl polymorphisms with drug toxicity
Polymorphisms rs number Amino acid exchange Location Drugs Drug toxicity/Disease/Observation References
G4002A rs2239330 No change Exon 28 Irinotecan Neutropenia/Solid tumor/Correlation [54]
Methotrexate Overall MTX toxicity/Rheumatoid arthritis/No 
correlation
[46]
IVS11 -48C > T rs3765129 No change Intron 11 Irinotecan Neutropenia/Solid tumor/Correlation [54]
IVS9 A8G rs35588 No change Intron 9 Irinotecan Neutropenia/Solid tumor/No correlation [54]
T1684C rs35605 No change Exon 13 Irinotecan Neutropenia/Solid tumor/No correlation [54]
IVS30 A18G rs212088 No change Intron 30 Irinotecan Neutropenia/Solid tumor/No correlation [54]
IVS3 G-3198A rsll075291 No change Intron 3 Methotrexate Hepatic and gastrointestinal toxicity/Psoriasis/
Correlation
[49]
IVS4 G409A rsl967120 No change Intron 4 Methotrexate Hepatic and gastrointestinal toxicity/Psoriasis/
Correlation
[49]
IVS5 G413A rs3784862 No change Intron 5 Methotrexate Hepatic and gastrointestinal toxicity/Psoriasis/
Correlation
[49]
IVS5 A-7942G rs246240 No change Intron 5 Methotrexate Hepatic and gastrointestinal toxicity/Psoriasis/
Correlation
[49]
IVS5 G-1641A rs3784864 No change Intron 5 Methotrexate Hepatic and gastrointestinal toxicity/Psoriasis/
Correlation
[49]
IVS23 G-1960A rs2238476 No change Intron 23 Methotrexate Hepatic and gastrointestinal toxicity/Psoriasis/
Correlation
[49]
IVS14 C115T No change Intron 14 Methotrexate Overall MTX toxicity/Rheumatoid arthritis/No 
correlation
[46]
IVS18 C-30G rs2074087 No change Intron 18 Methotrexate Overall MTX toxicity/Rheumatoid arthritis/No 
correlation
[46]
G2012T rs45511401 Gly671Val Exon 16 Doxorubicin Cardiotoxicity/NHL/Correlation [56]
IVS16 A1695T rs3887412 No change Intron 16 Vincristine Peripheral neuropathy/Multiple myeloma/Correlation [55]
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Tab. 5
Association of MRP1/ABCC1 polymorpliisms witli disease susceptibility and severity
Polymorphisms rs number Amino acid exchange Location Diseases Phenotype/Observation References
3′-UTRT866A rs212090 No change 3′-UTR Lung cancer Susceptibility/Correlation [58]
COPD Severity/Correlation [61]
3′-UTR C543T rs3743527 No change 3′-UTR Lung cancer Susceptibility/No correlation [58]
3′-UTRT1512C rs212091 No change 3′-UTR Lung cancer Susceptibility/No correlation [58]
T825C rs246221 No change Exon 8 Autism Susceptibility/No correlation [73]
G2168A r9tt48356 Arg723Gln Exon 17 Lung cancer Susceptibility/Correlation [59]
5′-UTR G -260C rs504348 No change Promoter Cystic fibrosis Severity/Correlation [60]
3′-UTR G3361A rs4148382 No change 3′-UTR COPD Severity/Correlation [61]
Lung function Severity/Correlation [51]
5′-UTR C435G rs504348 No change 5′-UTR COPD Severity/No correlation [61]
IVS1 T5977G rs4781699 No change Intron 1 COPD Severity/No correlation [61]
IVS14 C-1575T rs35621 No change Intron 14 COPD Severity/No correlation [61]
Lung function Severity/Correlation [51]
3′-UTR A2615G rs212093 No change 3′-UTR Lung function Severity/Correlation [51]
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